Disease · MONDO_0005611

bladder transitional cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bladder transitional cell carcinoma. Diseases, record MONDO_0005611. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005611

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bladder transitional cell carcinoma; Open Targets
Open Targets ID: MONDO_0005611; Open Targets
Other names: bladder urothelial cancer, bladder urothelial carcinoma, transitional cell carcinoma of bladder, transitional cell carcinoma of the urinary bladder, urinary bladder transitional cell carcinoma, urinary bladder urothelial carcinoma, urothelial bladder carcinoma, urothelial carcinoma of the urinary bladder; Open Targets
Disease Ontology: DOID:4006; Disease Ontology
NCI Thesaurus: C39851; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 21 of its 66 drugs, from ClinicalTrials.gov; Open Targets

Drugs66

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	23	23	23	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	10	10	9	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
BCG VACCINE	CHEMBL2108905	Vaccine component	Phase 3	ClinicalTrials.gov	5	5	0	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 66

See all 66 drugs

Targets74

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 74

See all 74 targets

Trials81

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02302807	A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]	Phase 3	931	2018-04-11	Bladder Cancer	ATEZOLIZUMAB, DOCETAXEL, PACLITAXEL, VINFLUNINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02108652	A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)	Phase 2	310	2017-01-04	Bladder Cancer	ATEZOLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01282463	Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma	Phase 2	148	2019-07-02	Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis	DOCETAXEL, ICRUCUMAB, RAMUCIRUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02951767	A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)	Phase 2	119	2017-04-21	Bladder Cancer	ATEZOLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04004221	Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer	Phase 2	113	2023-03-16	Locally Advanced or Metastatic Urothelial Bladder Cancer	TISLELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00055601	Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer	Phase 2	97	2016-08-10	Bladder Cancer	CISPLATIN, FLUOROURACIL, GEMCITABINE, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02563561	A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)	Phase 3	62	2021-09-27	Bladder Cancer	APAZIQUONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02621151	Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder	Phase 2	60	2025-10-07	Muscle-invasive Urothelial Cancer of the Bladder	GEMCITABINE, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00234039	S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin	Phase 2	58	2012-12-18	Bladder Cancer	GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00981656	Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer	Phase 2	37	2022-04-25	Bladder Cancer	CISPLATIN, FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 81

See all 81 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: deaths from any cause	393 of 443	379 of 459	902	NCT02302807	Trial comparisons
Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: serious adverse events	189 of 443	192 of 459	902	NCT02302807	Trial comparisons
Pelvic RT + Paclitaxel + Cisplatin vs Pelvic RT + Fluorouracil + Cisplatin: serious adverse events	43 of 46	39 of 47	93	NCT00055601	Trial comparisons
Bacillus Calmette-Guerin (BCG) + PANVAC vs Bacillus Calmette-Guerin (BCG) Alone: Number of Participants With Serious and Non-Serious Adverse Events	16 of 16	13 of 15	31	NCT02015104	Trial comparisons
BCG + PANVAC vs BCG Alone: deaths from any cause	3 of 15	2 of 15	30	NCT02015104	Trial comparisons
BCG + PANVAC vs BCG Alone: serious adverse events	3 of 15	3 of 15	30	NCT02015104	Trial comparisons
Cohort 1 (UBC) vs Cohort 2 (Pancreatic Cancer/Cholangiocarcinoma): deaths from any cause	7 of 13	1 of 7	20	NCT02999672	Trial comparisons
Cohort 1 (UBC) vs Cohort 2 (Pancreatic Cancer/Cholangiocarcinoma): serious adverse events	6 of 13	2 of 7	20	NCT02999672	Trial comparisons

Papers from its trials116

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33727028	RESULT	1	PubMed
33047430	RESULT	1	PubMed
32620210	RESULT	1	PubMed
31686036	RESULT	1	PubMed
29963784	RESULT	1	PubMed
29500551	RESULT	1	PubMed
29329894	RESULT	1	PubMed
28625005	RESULT	1	PubMed
28453896	RESULT	1	PubMed
28388418	RESULT	1	PubMed

1 to 10 of 116

See all 116 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005611

GET https://conductscience.org/api/diseases/v1/MONDO_0005611/drugs?page=2

API reference For AI assistants